December 15, 2017 / 2:42 PM / in a month

BRIEF-FDA Lifts Clinical Hold On Fitusiran

Dec 15 (Reuters) - Alnylam Pharmaceuticals Inc:

* FDA LIFTS CLINICAL HOLD ON FITUSIRAN

* FDA LIFTS CLINICAL HOLD ON FITUSIRAN

* ALNYLAM PHARMACEUTICALS INC - CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017

* ALNYLAM - FDA LIFTED HOLD ON CLINICAL STUDIES WITH FITUSIRAN, INCLUDING PHASE 2 OPEN-LABEL EXTENSION STUDY, ATLAS PHASE 3 PROGRAM

* ALNYLAM PHARMA - FDA HAS APPROVED PROTOCOL AMENDMENTS, OTHER UPDATED CLINICAL MATERIALS FOR FITUSIRAN STUDIES

* ALNYLAM - CO, FDA HAD PREVIOUSLY REACHED ALIGNMENT ON NEW CLINICAL RISK MITIGATION MEASURES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below